C4 Therapeutics Inc expected to post a loss of 66 cents a share - Earnings Preview

C4 Therapeutics

30/10/2023 13:34

* C4 Therapeutics Inc  CCCC.OQ   CCCC.O  is expected to show
a
fall in quarterly revenue when it reports  results 
    * The Watertown Massachusetts-based  company is expected to
report
 a 19.2% decrease in revenue to $5.46 million from $6.75 million
a year ago, according to the mean estimate from 8 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for C4 Therapeutics Inc
is
for a loss of 66 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 3
"hold" and 2 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for C4
Therapeutics
Inc is $15​, above​ its last closing price of $1.39. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.69       -0.69      -0.73     Missed  -6.1
 Mar. 31 2023  -0.73       -0.75      -0.71     Beat    4.8
 Dec. 31 2022  -0.73       -0.74      -0.77     Missed  -3.5​
 Sep. 30 2022  -0.65       -0.67      -0.65     Beat    3
 ​​Jun.        -0.70       -0.69      -0.56     Beat    19.2
 30 2022                                                
 Mar. 31 2022  -0.56       -0.58      -0.65     Missed  -12.3​
 Dec. 31 2021  -0.58       -0.58      -0.31     Beat    46.8
 Sep. 30 2021  -0.57       -0.59      -0.51     Beat    13.8
 This summary was machine generated October 30 at 13:34 GMT.  All
figures in US dollars  unless otherwise stated